Atara Biotherapeutics/ATRA

$0.71

-1.41%
-
1D1W1MYTD1YMAX

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.

Ticker

ATRA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Pascal Touchon

Employees

225

Headquarters

Thousand oaks, United States

ATRA Metrics

BasicAdvanced
$84.51M
Market cap
-
P/E ratio
-$2.61
EPS
0.70
Beta
-
Dividend rate
$84.51M
0.7
$3.08
$0.20
2.8M
0.716
0.648
-101.91%
-2,014.86%
-172.16%
9.857
-86.51%
-16.7%

What the Analysts think about ATRA

Analyst Ratings

Majority rating from 7 analysts.
Hold

Price Targets

Average projection from 4 analysts.
491.55% upside
High $13.00
Low $0.50
$0.71
Current price
$4.20
Average price target

ATRA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,438.09% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$4.2M
100%
Net income
$-60.4M
-13.34%
Profit margin
-1,438.09%
-56.67%

ATRA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 16.18%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.72
-$0.68
-$0.66
-$0.56
-
Expected
-$0.39
-$0.67
-$0.66
-$0.48
-$0.23
Surprise
83.81%
1.13%
-0.3%
16.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Atara Biotherapeutics stock?

Atara Biotherapeutics (ATRA) has a market cap of $84.51M as of April 15, 2024.

What is the P/E ratio for Atara Biotherapeutics stock?

The price to earnings (P/E) ratio for Atara Biotherapeutics (ATRA) stock is 0 as of April 15, 2024.

Does Atara Biotherapeutics stock pay dividends?

No, Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Atara Biotherapeutics dividend payment date?

Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders.

What is the beta indicator for Atara Biotherapeutics?

Atara Biotherapeutics (ATRA) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Atara Biotherapeutics stock price target?

The target price for Atara Biotherapeutics (ATRA) stock is $4.2, which is 491.55% above the current price of $0.71. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Atara Biotherapeutics stock

Buy or sell Atara Biotherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing